UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934
For the Month of June 2024
Commission File Number: 001-37710
HUTCHMED (CHINA) LIMITED
(Translation of registrant’s name into English)
48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ⌧ Form 40-F ◻
HUTCHMED (CHINA) LIMITED
Form 6-K
EXHIBIT INDEX
Exhibit No. |
| Description |
| | |
Exhibit 99.1 | | Announcement relating to notice of announcement of 2024 interim results |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| HUTCHMED (CHINA) LIMITED | |
| | |
| | |
| By: | /s/ Johnny Cheng |
| Name: | Johnny Cheng |
| Title: | Chief Financial Officer |
Date: June 26, 2024
3
Exhibit 99.1
HUTCHMED to Announce 2024 Half-Year Financial Results
Hong Kong, Shanghai & Florham Park, NJ — Wednesday, June 26, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its interim results for the six months ended June 30, 2024 on Wednesday, July 31, 2024 at 7:00 am Eastern Daylight Time (EDT) / 12:00 noon British Summer Time (BST) / 7:00 pm Hong Kong Time (HKT).
Analysts and investors are invited to join a conference call and audio webcast presentation with Q&A, conducted by HUTCHMED management.
The English conference call and audio webcast will be held on Wednesday, July 31, 2024, at 8:00 am EDT (1:00 pm BST / 8:00 pm HKT). The Chinese (Putonghua) webcast will be held at 8:30 am HKT / 1:30 am BST on Thursday, August 1, 2024 (8:30 pm EDT on Wednesday, July 31, 2024). Both webcasts will be available live via the company website at www.hutch-med.com/event/. The presentation will be available for downloading before the conference call begins. Details of the conference call dial-in will be provided in the financial results announcement and on the company website. A replay will also be available on the website shortly after the event.
About HUTCHMED
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has approximately 5,000 personnel across all its companies, at the center of which is a team of about 1,800 in oncology/immunology. Since inception it has focused on bringing cancer drug candidates from in-house discovery to patients around the world, with its first three oncology drugs marketed in China, the first of which is also marketed in the U.S. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.
CONTACTS
Investor Enquiries | +852 2121 8200 / ir@hutch-med.com |
| |
Media Enquiries | |
Ben Atwell / Alex Shaw, FTI Consulting | +44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile) / HUTCHMED@fticonsulting.com |
Zhou Yi, Brunswick | +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com |
| |
Nominated Advisor | |
Atholl Tweedie / Freddy Crossley / Rupert Dearden, Panmure Gordon | +44 (20) 7886 2500 |
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